Boiko Anastasiia S, Mednova Irina A, Mikhalitskaya Ekaterina V, Paderina Diana Z, Petkun Dmitry A, Kornetova Elena G, Bokhan Nikolay A, Ivanova Svetlana A
Mental Health Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, Russia.
Psychiatry, Addictology and Psychotherapy Department, Siberian State Medical University, Tomsk, Russia.
Front Psychiatry. 2025 May 19;16:1556079. doi: 10.3389/fpsyt.2025.1556079. eCollection 2025.
The search for the genetic basis of the leading symptom domains of schizophrenia is of interest. BDNF is a universal neurotrophin that promotes brain development and neuroplasticity. Our aim was to study polymorphisms of the gene and serum levels of BDNF in schizophrenia and to analyze the concentration of this marker depending on clinical and genetic characteristics.
A clinical and biological examination of 123 patients with paranoid schizophrenia (F20.0, ICD-10) was conducted. The control group consisted of 193 healthy individuals. Genotyping of polymorphisms (rs6265 and rs11030104) was performed by RT-PCR. BDNF concentration was determined using xMAP technology. Statistical data processing was performed in SPSS software.
A lower BDNF concentration was found in schizophrenia patients than in healthy individuals. Clinical characteristics of the disease, such as duration of the disease and leading clinical symptoms do not affect the level of BDNF. The continuous type of course is characterized by a tendency to decrease the BDNF serum concentration compared to the episodic type. The distribution of rs6265 genotypes differed significantly between the groups of schizophrenia patients and healthy individuals. The TT genotype was more common among the patients and had a predisposing effect on schizophrenia. Serum levels of BDNF did not differ between the patients with different genotypes.
Our results support a potential value of studied BDNF protein and gene as a neurobiological marker for schizophrenia pathogenesis and clinical characteristics. Further case-control studies on the gene and peripheral BDNF levels with larger sample sizes and different ethnic groups are needed to better understand the pathogenesis of the schizophrenia.
探寻精神分裂症主要症状领域的遗传基础备受关注。脑源性神经营养因子（BDNF）是一种促进大脑发育和神经可塑性的通用神经营养因子。我们的目的是研究精神分裂症患者中该基因的多态性及BDNF的血清水平，并根据临床和遗传特征分析该标志物的浓度。
对123例偏执型精神分裂症患者（F20.0，ICD - 10）进行了临床和生物学检查。对照组由193名健康个体组成。通过逆转录聚合酶链反应（RT - PCR）对多态性（rs6265和rs11030104）进行基因分型。使用xMAP技术测定BDNF浓度。在SPSS软件中进行统计数据处理。
发现精神分裂症患者的BDNF浓度低于健康个体。疾病的临床特征，如病程和主要临床症状，不影响BDNF水平。与发作型相比，连续型病程的特点是BDNF血清浓度有降低的趋势。精神分裂症患者组和健康个体组之间rs6265基因型的分布存在显著差异。TT基因型在患者中更常见，对精神分裂症有易感作用。不同基因型患者的BDNF血清水平无差异。
我们的结果支持所研究的BDNF蛋白和基因作为精神分裂症发病机制和临床特征的神经生物学标志物的潜在价值。需要进一步开展更大样本量和不同种族的关于该基因和外周BDNF水平的病例对照研究，以更好地理解精神分裂症的发病机制。
